PharmaDrug takes its first step to begin retail psychedelic sales in the legal market for psychedelic drugs in the Netherlands.
Exploring the companies and themes that make up this emerging and exciting new sector
Revive Therapeutics Advancing Drug Delivery Technology for Psychedelics Developed Prototypes of Orally Dissolvable Thin Film For Psilocybin
Revive develops a new tannin-chitosan composite as a psychedelics delivery system.
Canadians LEGALLY Using Psilocybin: A Big Step Forward
For the first time since the 1970's, a small group of Canadians have been granted (federal) permission to legally use psilocybin for medicinal purposes.
Going To War For Legal Psychedelic Drugs
The need for the medicinal benefits of psychedelic drugs is producing unlikely allies.
Novamind Closes the Acquisition of Cedar Psychiatry, a Leading Psychedelic Therapy Organization in the U.S.
Novamind acquires Utah-based Cedar Psychiatry and Cedar Clinical Research for CAD$3.05 million.
Big Pharma: Friend or Foe of Psychedelic Drugs?
Big Pharma has strong incentives to embrace psychedelics. But will its predatory business model turn drug companies against these drugs?
Palliative Canadians endure punishing waits while Health Minister delays approval of Psilocybin mushrooms; TheraPsil expands effort to Ontario
More pressure on Ottawa to move forward on legalization of psilocybin.
Numinus and Together We Can Partner to Support Addiction Recovery and Mental Wellness
Numinus establishes a partnership with one of Canada's largest addiction treatment organizations.
MindMed Completes Dosing 18-MC Phase 1 Study
MindMed completes its Phase 1 study of its non-hallucinogenic formulation of ibogaine.
Mydecine Building Its Psychedelics Footprint
Mydecine Innovations Group has been building momentum with a string of recent announcements.
Psychedelics Investing 101: Creating a Basket of Psychedelics Stocks
Intelligent diversification is the key to investing in this emerging industry.
The Lundquist Institute Accepts a $1.75 Million Anonymous Donation to Improve the Quality of Dying
Funding to evaluate the potential of psilocybin to ease end-of-life distress.